Third Bench (OTC:THBD) Stock, Quote.Headers.trade-ideas

Third Bench Inc is engaged in architectural millwork and dealers in the cabinetry, kitchen, and bath areas. It offers products in categories such as Residential Cabinets and countertops and commercial millwork throughout the Western U.S. for customers from California to Texas. The Company is a holding company for six subsidiary companies operating as an architectural millwork and dealers in the cabinetry, kitchen and bath areas.

Third Bench Inc

Hedge fund manager Bill Ackman sent shares of UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) lower with a tweet alleging overstated profits, which comes as the health insurance company faces more scrutiny after the death <a href="https://www.benzinga.com/25/01/43195956/unitedhealth-announces-replacement-for-murdered-executive-heres-who-will-lead-insurance-unit">of an executive.</a>
What Happened: The health insurance sector faces pressure after the<a href="https://www.benzinga.com/general/health-care/24/12/42316904/unitedhealthcare-ceo-brian-thompson-fatally-shot-outside-nyc-hotel"> killing of UnitedHealthcare CEO</a> Brian Thompson put a bigger spotlight on potentially high claim denial rates, with the alleged murderer accusing the company of prioritizing profits over people.
Ackman stirred further concerns for UnitedHealth Group with a tweet on Tuesday night.
"I would not be surprised to find that the company's profitability is massively overstated due to its denial of medically necessary procedures and patient care," Ackman said in the since-deleted tweet.
Ackman suggested he would short the stock if he still shorted stocks.
The hedge funder called on the SEC to investigate UnitedHealth Group.
Now, Ackman himself could face an SEC probe. The insurance company said they contacted the SEC with concerns about Ackman's post, as reported by <a href="https://www.bloomberg.com/news/articles/2025-02-05/unitedhealth-raised-concerns-with-sec-on-ackman-post-on-profits?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>.
"Health insurance has long been subject to significant regulatory oversight and earnings caps," UnitedHealth said in a statement.
The company said that people like Ackman claiming that insurance companies "can somehow over-earn are grossly misinformed."
Read Also: <a href="https://www.benzinga.com/top-stories/24/08/40423891/buffett-musk-wood-cuban-or-ackman-who-do-investors-trust-most-with-life-savings-poll-shows-it-isnt-e">Buffett, Musk, Wood, Cuban Or Ackman: Who Do Investors Trust Most With Life Savings? Poll Shows It Isn&#8217;t Even Close</a>
Why It's Important: Ackman's assertion that profitability was "massively overstated" follows the company&#8217;s <a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls">Jan. 16 earnings report.</a>
The company has faced many questions about its profitability and its claims approval and denial process as alleged killer Luigi Mangione allegedly targeted Thompson and UnitedHealth due to the company's position in the health insurance sector.
UnitedHealthcare is the largest individual player in Medicare Advantage with 7.8 million members, the company&#8217;s latest earnings report revealed. The company also has 4.3 million members enrolled in Medicare supplement plans through UnitedHealthcare. It also has 3 million people enrolled in standalone Part D coverage.
Thompson&#8217;s death and&nbsp;<a href="https://www.benzinga.com/24/12/42605759/luigi-mangione-faces-death-penalty-details-show-attack-planned-for-months-the-target-is-insuranceit-checks-every-box" target="_blank" rel="noreferrer noopener">the possible motive&nbsp;</a>behind his killing have drawn scrutiny to the health insurance sector, including reports of high claim denial rates by companies like UnitedHealth Group.
UnitedHealth CEO&nbsp;Andrew Witty&nbsp;acknowledged the pressure on the health insurance sector during the company&#8217;s earnings call. The industry needs to be &#8220;less confusing, less complex and less costly&#8221; for patients, he said.
Mangione faces New York state charges along&nbsp;<a href="https://www.benzinga.com/news/legal/24/12/42541669/luigi-mangione-indicted-on-first-degree-murder-charges-in-unitedhealthcare-ceos-death-senseless-act-of-violence" target="_blank" rel="noreferrer noopener">with federal charges</a>. He also faces the potential of the death penalty if found guilty of first-degree murder on federal charges.
Mangione&nbsp;<a href="https://www.benzinga.com/24/12/42655562/luigi-mangione-suspected-ceo-assassin-pleads-not-guilty-in-new-york-court" target="_blank" rel="noreferrer noopener">pleaded not guilty</a>&nbsp;in New York on Dec. 23. He is expected to appear in federal court on Feb. 21.
UNH, DIA Price Action:&nbsp;UnitedHealth stock is down 1.6% to $536.70 on Wednesday. Shares hit a daily low of $521.91 before recovering slightly. The stock has traded between $436.38 and $630.73 over the past year.
The quick drop in UnitedHealth stock to open Wednesday's trading session also saw ETFs that track the Dow Jones Industrial Average like the SPDR Dow Jones Industrial ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fall.
The SPDR Dow Jones Industrial ETF fell to start the day before recovering. The ETF is now up 0.3% on the day at the time of writing.
UnitedHealth is the second largest holding in the Dow Jones ETF and the second largest weighting of the index, which weighs stocks by stock price and not market capitalization.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42544499/luigi-mangione-documentaries-in-the-works-from-award-winning-creators-and-possibly-rapper-50-cent" target="_blank" rel="noreferrer noopener">Luigi Mangione Documentaries In The Works From Award-Winning Creators — And Possibly Rapper 50 Cent</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Movers

Trading Ideas

Insurance

SPDR Dow Jones Industrial Average ETF Trust

Bill Ackman Sends UnitedHealth Stock Lower With Deleted Tweet: Here's What He Said

Macro Economic Events

Market Summary

Economics

General

GOOG

GOOGL

Citigourp Global Markets 2% Protected Notes Linked To The Djia

UBER

Benzinga Market Summary: Alphabet And Uber Shares Fall On Earnings, Gold Rises On Trade Tensions And Dollar Weakness, PDD Stock Falls On Reports US Will Add Temu to 'Forced Labor' List.

Crypto analyst Michaёl van de Poppe urges investors to hold their crypto assets, emphasizing that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is fairly valued while altcoins <a href="https://www.benzinga.com/money/best-altcoins">remain heavily undervalued.</a> 
What Happened: Van de Poppe <a href="https://x.com/CryptoMichNL/status/1887169793322897758">highlighted</a> on Wednesday on X that the crypto market is currently experiencing one of the most extreme bearish sentiments in its history, following a prolonged period of capitulation. 
Many altcoin investors have suffered major losses over the past 6-12 months, but he believes the tide is turning.
Despite market skepticism, Bitcoin breaking past $150,000 is a realistic scenario, with many underestimating the potential for exponential growth. 
The fear of diminishing returns, a mindset shaped by previous bear markets, has caused many to doubt Bitcoin's long-term upside.
However, there are strong bullish tailwinds, particularly relating government adoption of Bitcoin, such as:
<ul>
<li>Discussions on adding <a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43489967/the-trump-bitcoin-reserve-ushers-in-golden-age#:~:text=The%20Bitcoin%20Reserve%20Act%20requires,the%20course%20of%20criminal%20investigations.">BTC to national reserves</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43504042/blackrock-to-launch-bitcoin-investment-product-in-europe">Institutional capital</a> flowing into crypto</li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43347567/institutional-bitcoin-buyer-boom-czech-national-bank-approves-reserve-proposal-norways-sovereign-wealth-fund-increases-exposure">Banks integrating Bitcoin</a> custody solutions</li>
</ul>
Van de Poppe draws comparisons to past market booms, such as the Dotcom bubble (1995-1999) and the 2017 crypto cycle, where Bitcoin hit $20,000 and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) peaked at $1,400. 
This time, he predicts a longer, more extended bull cycle that could propel BTC to $300,000-$500,000 this year, with a potential $1 million target in the coming years.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43494611/bitcoin-to-reach-500000-before-trump-leaves-office-standard-chartered">Bitcoin To Reach $500,000 Before Trump Leaves Office: Standard Chartered</a>
What's Next: As the global macro landscape shifts, especially with China's evolving policies, altcoins are poised for significant growth. 
Van de Poppe argues that the market remains deeply undervalued, and many traders stuck in "bear market PTSD" risk missing out on what could be the final, massive bull run of this cycle.
Additionally, decentralized finance (DeFi) is becoming more integrated with traditional banking, with financial institutions leveraging DeFi platforms to offer higher yields. 
This could further accelerate mainstream crypto adoption.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43492011/exclusive-crypto-czar-charm-offensive-welcomed-but-experts-wonder-will-us-policy-deliver">EXCLUSIVE: &#8216;Crypto Czar&#8217; Charm Offensive Welcomed, But Experts Wonder: Will US Policy Deliver?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

Bitcoin Struggling But 'Perfect Storm' Will Take It To $500,000, Ethereum To $20,000, Trader Predicts

In the preceding three months, 4 analysts have released ratings for CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $21.75, a high estimate of $23.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 16.0% from the previous average price target of $18.75.
<img src="https://www.benzinga.com/files/images/story/2025/1738782061_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of CVRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVRx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CVRx compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into CVRx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering CVRx: A Closer Look</h2>
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
<h3>Understanding the Numbers: CVRx's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, CVRx showcased positive performance, achieving a revenue growth rate of 27.23% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CVRx's net margin excels beyond industry benchmarks, reaching -97.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -21.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.71%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVRx's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CVRX

What 4 Analyst Ratings Have To Say About CVRx

Analysts' ratings for Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $79.11, with a high estimate of $92.00 and a low estimate of $68.00. Marking an increase of 13.19%, the current average surpasses the previous average price target of $69.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1738782053_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Intapp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intapp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Intapp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Intapp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Intapp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intapp analyst ratings.</a>
<h2>Delving into Intapp's Background</h2>
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, investment banking, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
<h3>Financial Milestones: Intapp's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intapp displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 16.96%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Intapp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.8%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Intapp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.07%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Intapp's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.61%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Intapp's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTA

Breaking Down Intapp: 9 Analysts Share Their Views

In the preceding three months, 10 analysts have released ratings for Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Pentair and provided 12-month price targets. The average target is $120.0, accompanied by a high estimate of $126.00 and a low estimate of $114.00. This current average has increased by 4.45% from the previous average price target of $114.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1738782040_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Pentair is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$114.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Sector Weight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Nigel Coe</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pentair. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pentair compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Pentair's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pentair's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PNR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pentair analyst ratings.</a>
<h2>All You Need to Know About Pentair</h2>
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2023.
<h3>Breaking Down Pentair's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Pentair's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -1.53%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 14.05%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Pentair's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pentair's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.14%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.5.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Pentair: Insights From 10 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $104.14, with a high estimate of $115.00 and a low estimate of $93.00. Witnessing a positive shift, the current average has risen by 5.04% from the previous average price target of $99.14.
<img src="https://www.benzinga.com/files/images/story/2025/1738782031_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of WEC Energy Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Neil Kalton</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Weisel</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$97.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WEC Energy Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of WEC Energy Group compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of WEC Energy Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into WEC Energy Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WEC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WEC Energy Group analyst ratings.</a>
<h2>About WEC Energy Group</h2>
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 48% electric generation and distribution, 36% gas distribution, 10% electric transmission, and 6% unregulated renewable energy.
<h3>WEC Energy Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, WEC Energy Group faced challenges, resulting in a decline of approximately -4.8% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: WEC Energy Group's net margin is impressive, surpassing industry averages. With a net margin of 12.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): WEC Energy Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.99%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): WEC Energy Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.53%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.6.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing WEC Energy Group: Insights From 7 Financial Analysts

Powell Industries's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NYSE">POWL</a>) short percent of float has fallen 5.44% since its last report. The company recently reported that it has 1.31 million shares sold short, which is 16.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Powell Industries Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738782026_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Powell Industries has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Powell Industries's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Powell Industries's peer group average for short interest as a percentage of float is 10.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

POWL

Looking Into Powell Industries's Recent Short Interest

7 analysts have expressed a variety of opinions on Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.43, along with a high estimate of $56.00 and a low estimate of $49.00. Experiencing a 6.61% decline, the current average is now lower than the previous average price target of $56.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1738782023_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Archer-Daniels Midland's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Salvator Tiano</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$54.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Archer-Daniels Midland. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Archer-Daniels Midland compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Archer-Daniels Midland's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Archer-Daniels Midland's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Archer-Daniels Midland analyst ratings.</a>
<h2>Discovering Archer-Daniels Midland: A Closer Look</h2>
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
<h3>Financial Insights: Archer-Daniels Midland</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Archer-Daniels Midland's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.1% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Archer-Daniels Midland's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Archer-Daniels Midland's ROE excels beyond industry benchmarks, reaching 0.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.03%, the company showcases effective utilization of assets.
Debt Management: Archer-Daniels Midland's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Archer-Daniels Midland In The Eyes Of 7 Experts

Loews's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) short percent of float has risen 10.89% since its last report. The company recently reported that it has 1.96 million shares sold short, which is 1.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Loews Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738782020_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Loews has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Loews's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Loews's peer group average for short interest as a percentage of float is 2.03%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Loews's Recent Short Interest

Electronic Arts's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EA#NYSE">EA</a>) short percent of float has fallen 3.97% since its last report. The company recently reported that it has 6.74 million shares sold short, which is 2.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Electronic Arts Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738782014_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Electronic Arts has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Electronic Arts's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Electronic Arts's peer group average for short interest as a percentage of float is 3.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Electronic Arts's Recent Short Interest

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Atkore and provided 12-month price targets. The average target is $95.67, accompanied by a high estimate of $115.00 and a low estimate of $80.00. This current average represents a 14.88% decrease from the previous average price target of $112.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1738782015_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Atkore by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Justin Clare</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$102.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$93.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Atkore. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Atkore compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Atkore's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Atkore's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ATKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Atkore analyst ratings.</a>
<h2>Delving into Atkore's Background</h2>
Atkore Inc is a diversified industrials company and a manufacturer of electrical, mechanical, and safety infrastructure solutions. Atkore has two business segments; Electrical and Safety and Infrastructure. Net sales are highest in the electrical business line. The key product categories in the electrical segment are PVC conduit, steel conduit, and PVC-coated conduit, which are staples for electrical distributors. The key product categories in the safety and infrastructure segment include in-line galvanized mechanical tubes, metal framing and related fittings, and security bollards. Also, the company provides ancillary services to customers in the form of slitting and cutting structural steel sheets. Geographically, the company derives its key revenue from the United States.
<h3>Breaking Down Atkore's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Atkore faced challenges, resulting in a decline of approximately -9.38% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Atkore's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.17%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Atkore's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Atkore's debt-to-equity ratio is below the industry average at 0.62, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATKR

Forecasting The Future: 6 Analyst Projections For Atkore

<a href="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs" title="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs">https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs</a>

GOVX

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

Let me tell you something about Warren Buffett that might shock you.
You know all those Buffett quotes you see floating around about buying wonderful companies at fair prices and holding them forever? The ones that get shared endlessly on social media by folks who think they&#8217;re investment gurus because they bought some Apple stock?
Well, here&#8217;s the truth: That&#8217;s not how Warren got rich in the first place.
Now, don&#8217;t get me wrong. Buying great businesses at reasonable prices is a fantastic strategy &#8211; if you&#8217;re sitting on billions of dollars like Berkshire Hathaway is today. But for those of us mere mortals trying to build wealth in the stock market, we&#8217;d be better served following the Warren Buffett of the 1950s and 1960s.
You see, the young Warren Buffett learned his craft from the grandfather of value investing himself, Ben Graham, at Columbia University. Then he went to work for Graham at Graham-Newman, where he really got his hands dirty with deep value investing. And let me tell you, he wasn&#8217;t looking for wonderful businesses back then &#8211; he was hunting for cheap stocks in solid companies that Wall Street had tossed in the bargain bin.
I&#8217;ve spent countless hours poring over Buffett&#8217;s partnership letters from 1957 to 1970, and they&#8217;re an absolute goldmine of investment wisdom. They show us exactly how he built his initial fortune, and more importantly, how we can apply those same principles today.
The Four Ways Buffett Really Made His Money
Buffett divided his investments into four distinct categories, and understanding these is crucial if you want to follow in his footsteps:
1. The Private Owner Approach
This was Buffett&#8217;s bread and butter. He&#8217;d find companies that were dirt cheap compared to their actual worth and buy them like he was going to own them forever. He wasn&#8217;t looking for quarterly earnings beats or momentum plays &#8211; he was looking for real businesses selling for less than they were worth.
2. The Relatively Undervalued Play
These weren&#8217;t the screaming bargains of category one, but they were still companies trading below their intrinsic value. Think of it as buying dollar bills for 70 cents instead of 50 cents. Not as sexy, but still profitable if you&#8217;re patient.
3. The Work-Out Situation
This is where Buffett really showed his creativity. He&#8217;d find special situations &#8211; mergers, spinoffs, reorganizations &#8211; where he could make money regardless of what the broader market was doing. It&#8217;s like finding a $20 bill in the street &#8211; it doesn&#8217;t matter if the stock market is up or down that day.
4. The Control Play
This is where things get really interesting. Sometimes Buffett would buy enough stock to influence company decisions. Take the Dempster Mill story &#8211; he bought a controlling stake in a company selling for $18 that had a book value of $72. That&#8217;s like buying a dollar for a quarter!
The Dempster Mill Case Study: A Master Class in Value Investing
Let me tell you about Dempster Mill, because it perfectly illustrates how Buffett operated back then. This wasn&#8217;t some wonderful business with great brands and high returns on capital. It was a boring old company making windmills and farm equipment in Nebraska.
But here&#8217;s the beautiful part &#8211; it was trading for $18 per share when it had a book value of $72. That&#8217;s the kind of discount that makes value investors salivate. Buffett slowly accumulated shares until he owned over 70% of the company. Then he brought in new management, cleaned house, and nearly tripled his money.
Was it pretty? No. Was it easy? Absolutely not. But it was profitable, and that&#8217;s what counts in this business.
The American Express Opportunity
Sometimes the market hands you a gift wrapped in newspaper headlines of doom and gloom. That&#8217;s exactly what happened with American Express during the Salad Oil Scandal of 1963. Everyone thought AmEx was going down in flames because of a massive fraud involving soybean oil warehouse receipts (yes, really).
The stock crashed 50%, which got Buffett&#8217;s attention. He did his homework, realized the core business was solid as a rock, and invested $13 million. This wasn&#8217;t just a cigar butt play &#8211; it was buying a great business when everyone else was running for the hills.
The Bottom Line
Here&#8217;s what really matters: Buffett has said multiple times that if he were managing smaller sums today, he&#8217;d go right back to investing the way he did in the partnership days. That should tell you something important.
For individual investors like us, there&#8217;s a fortune to be made following Buffett&#8217;s original playbook. Look for solid companies trading at deep discounts to their intrinsic value. Find special situations where you can make money regardless of market conditions. And when the market occasionally serves up a great business at a fire-sale price due to temporary problems, back up the truck.
The truth is, you don&#8217;t need to find the next Amazon to make money in the stock market. You just need to find things that are worth a dollar and buy them for 50 cents. That&#8217;s how Warren really got rich, and that&#8217;s exactly the kind of opportunities I&#8217;ll be bringing to you in my newest service on Benzinga Research.
Remember, the stock market is simply a mechanism for transferring money from the impatient to the patient. And I plan to be very, very patient.
<a href="https://www.benzinga.com/premium/ideas/trade-alerts//?utm_source=WebRD-0206&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">Your Exclusive Invitation to My New ‘Trade Alerts' Service</a>
As an Research Daily member, you're invited to secure a charter membership to my newest research service &#8211; at a massive discount.
This is your chance to get in BEFORE the public launch on Monday…
And potentially capture gains like 150%, 237%, and 664% from these dead simple to follow ‘Trade Alerts'
<a href="https://www.benzinga.com/premium/ideas/trade-alerts//?utm_source=WebRD-0206&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">See Charter Member Offer Details Here (Only 200 Spots Available)</a>
Image via Shutterstock

Opinion

The Real Way Warren Buffett Got Rich (And Why You Should Care)

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">are trading lower on Wednesday.</a>
Yesterday, the company reported fourth-quarter revenue of $7.66 billion, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst estimates</a> of $7.53 billion. The chipmaker reported fourth-quarter adjusted earnings of $1.09 per share, beating <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43480688/amd-q4-earnings-revenue-beat-eps-beat-data-center-continued-growth" rel="noreferrer noopener">analyst estimates of $1.08 per share.</a>
AMD expects first-quarter revenue of approximately $7.1 billion, plus or minus $300 million. The company&#8217;s revenue guidance represents year-over-year growth of approximately 30% at the midpoint.
Here are the analysts&#8217; <a target="_blank" href="https://www.benzinga.com/quote/AMD/analyst-ratings" rel="noreferrer noopener">takes on the earnings results:</a>
BofA Securities analyst Vivek Arya reiterated the Neutral rating on the stock, lowering the price forecast to $135 from $155.
The analyst noted the company&#8217;s struggle to carve out a niche against NVIDIA Corporation&#8216;s dominance and the rise of custom AI chips.
The analyst writes AMD&#8217;s fourth quarter was in line with expectations, with stronger PC sales offsetting weakness in data centers.
Arya adds that first quarter sales are expected to be modestly better, driven by consumer PC and gaming, unlike Intel Corporation&#8217;s weaker outlook.
For the AI GPU segment, the analyst now forecasts $7.5 billion in 2025, slightly lower than the previous $8 billion estimate.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43469715/amd-vs-qualcomm-a-semiconductor-showdown-ahead-of-earnings" rel="noreferrer noopener">AMD Vs. Qualcomm: Semiconductor Showdown Ahead Of Earnings</a>
Goldman Sachs analyst Toshiya Hari maintained Neutral rating on Advanced Micro Devices, lowering the price forecast to $125 from $129. The analyst raises 2025 and 2026 revenue estimates by 5% and 4% due to stronger Client and Gaming segments, despite lower Data Center and Embedded revenue.
Non-GAAP EPS estimates for 2025 and 2026 increase by 6% and 1%, reaching $4.56 and $6.10, driven by higher revenue, partly offset by lower gross margins and higher operating expenses.
The analyst also introduces 2027 revenue estimates of $46.6 billion (+18% year over year) and non-GAAP EPS of $7.66 (+26% year over year).
JP Morgan analyst Harlan Sur maintained the Neutral rating on Advanced Micro Devices, lowering the price forecast to $130 from $180.
The analyst notes Advanced Micro Devices&#8217; mixed demand in Embedded, with strong performance in aerospace/defense and test/emulation, but challenges in cyclical sectors like industrial and communication.
However, per Sur, these sectors will stabilize by mid-year as market recovery picks up in the second half. The analyst lowers forward estimates due to weaker-than-expected demand for data center GPUs.
Benchmark analyst Cody Acree reiterated the Buy rating on the stock, lowering the price forecast to $170 from $200.
The analyst views the company&#8217;s report and outlook as solid, attributing the softness in GPU guidance to a positive product transition.
Customers are eagerly awaiting the next-gen platform, which was pulled forward, Acree writes.
After surpassing its $5 billion AI GPU revenue goal for FY24, the company expects a slower revenue pace in the first half of 2025 as customers focus on existing programs while awaiting the MI350 platform release. The production ramp for MI350 has been moved up by a quarter, now expected in mid-2025 instead of the second half, Acree adds.
Rosenblatt analyst Hans Mosesmann reiterated the Buy rating, lowering the price forecast from $250 to $225.
Mosesmann lowers the 2025 MI300 series sales forecast to $7 billion from $9.2 billion, reflecting a flatter 2H24 to 1H25 product transition to MI325/350X.
Northland analyst Gus Richard reiterated the Outperform rating on AMD, with a price forecast of $175.
AI revenue is expected to stay flat in the first half of 2025 and the second half of 2024, raising concerns, but a stronger second half is anticipated, with $9.2 billion in AI revenue on the back of the MI350 in the latter half.
After being oversold, Advanced Micro Devices shares bounced, and the analyst recommends buying on weakness.
Price Action: AMD shares are trading lower by 7.82% to $110.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback" target="_blank" rel="noreferrer noopener">Trump&#8217;s Plan To Turn Gaza Into Seaside Resort, Remove 2 Million Palestinians Roundly Rejected By World Leaders</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Price Target

Reiteration

Markets

Tech

INTC

NVDA

AMD's AI Ambitions Face NVIDIA's Dominance—Analysts See Growth, But Challenges Remain

"We got really lucky about six years ago when we started exploring how cannabinoids might be used to treat drug-resistant infections," says Dr. Dana Lambert, CEO of Andira Pharmaceuticals, in an exclusive interview with <a href="https://www.benzinga.com/cannabis">Benzinga</a>.
Dr. Lambert doesn't speak like an academic. Despite holding a Ph.D. in pharmaceutical sciences, she talks like someone who has witnessed medicine fail firsthand. She began her career as a hospital pharmacist, working with critically ill patients — people battling cancer, severe infections and other conditions where existing treatments often fell short. 
She saw, up close, the limitations of conventional medicine, "particularly when it comes to treating drug-resistant infections and cancer-related conditions."
But instead of accepting those limitations as inevitable, she took a bold step: she left her clinical practice entirely to pursue pharmaceutical research. 
"I became increasingly interested in new therapeutic approaches, especially as research started emerging on the potential of cannabinoids in treating cancer and antimicrobial-resistant infections," she says.
That realization drove her to earn a Ph.D.; not because she wanted a career in academia, but because she needed the tools to create real-world solutions. 
"I'm probably the furthest thing from an academic scientist you'll ever meet," Lambert says. "I did it because I wanted to learn how to develop drugs and get involved in early-stage research and drug discovery."
What she and her team at Andira Pharmaceuticals uncovered was something that could change how the world fights infections. The discovery? Silvanex: a next-generation antimicrobial technology that could be the answer to drug-resistant "superbugs."
<h1 class="wp-block-heading">The Problem With Traditional Antimicrobials</h1>
"Most traditional antimicrobials — whether they're antibiotics, antifungals or even silver-based products — eventually lose effectiveness because bacteria and fungi evolve resistance over time. That's how we ended up in the antimicrobial resistance (AMR) crisis we're facing today," Lambert explains.
See also: <a href="https://www.benzinga.com/news/retail-sales/25/01/43281367/germanys-medical-cannabis-boom-prices-drop-below-4-20-gram-prescriptions-surge-1000">Germany&#8217;s Medical Cannabis Boom: Prices Drop Below $4.20/Gram, Prescriptions Surge 1,000%</a>
Antibiotic-resistant bacteria <a href="https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance">now kill</a> more than 1.27 million people annually, with drug-resistant infections contributing to nearly 4.95 million deaths worldwide in 2019 alone. If left unaddressed, AMR <a href="https://www.worldbank.org/en/topic/health/brief/antimicrobial-resistance-amr">could lead</a> to more than 39 million deaths between 2025 and 2050. 
The economic consequences are just as severe. The World Bank <a href="https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future">estimates</a> AMR could result in a GDP loss of $1 trillion to $3.4 trillion annually by 2030, with global healthcare costs rising by an additional $1 trillion by 2050. If no action is taken, AMR <a href="https://www.worldbank.org/en/news/press-release/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis">could cause</a> a 3.8% reduction in global GDP, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4967260/">costing the world economy</a> up to $100 trillion by mid-century.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="428" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15-1024x428.png" alt="" class="wp-image-767658" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15-1024x428.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15-300x125.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15-768x321.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15-1536x642.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05121941/Screen-Shot-2025-02-05-at-14.19.15.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The rise of drug-resistant infections like methicillin-resistant Staphylococcus aureus (MRSA) and Candida auris has intensified the urgency for new treatments. 
Candida auris, in particular, has become one of the most concerning fungal threats in modern healthcare, as some strains have become resistant to all available antifungal treatments. "With antimicrobial resistance, silver-based products just aren't cutting it anymore," Lambert says. "They don't have the clinical efficacy needed to protect people from infections."
Silver, once considered a promising antimicrobial alternative, also has limitations. It's widely used in wound dressings, medical textiles, and coatings, but its effectiveness is modest at best. For years, researchers have been trying to find ways to enhance silver's antimicrobial effects without increasing its toxicity. That's exactly what Andira Pharmaceuticals set out to do.
<h1 class="wp-block-heading">A Triple-Synergy Solution</h1>
Rather than relying on silver alone, Andira Pharmaceuticals took a different approach. Silvanex is based on a "triple-synergy" mechanism, combining silver with two cannabinoids: cannabichromene (CBC) and cannabigerol (CBG).
What makes it revolutionary is that instead of just slightly improving silver's antimicrobial properties, the combination increases silver's effectiveness by 800%.
"When you take cannabinoids by themselves, they may be effective against some types of bacteria or fungi, but not others. That makes them unreliable as stand-alone antimicrobial agents," Lambert explains. "But when combined with silver in the right way, the synergy makes silver exponentially more effective."
See also: <a href="https://www.benzinga.com/general/biotech/25/01/43278893/how-ozempic-and-legal-weed-are-changing-what-america-eats">How Ozempic And Legal Weed Are Changing What America Eats</a>
Silvanex has shown potent antimicrobial activity against a wide range of harmful bacteria — including drug-resistant superbugs.
The discovery didn't stop there. Silvanex also proved highly effective against fungal pathogens, an area where traditional antimicrobials have struggled.
"One of the most dangerous fungal infections today is Candida auris. The situation is so bad that certain strains are now resistant to all available antifungal drug treatments. That's why the CDC advises clinicians to consider investigational treatments for pan-resistant cases," Lambert adds.
But Silvanex changed that equation.
"Unlike conventional antimicrobials, it not only kills infectious microbes but may also help prevent resistance from developing," Lambert says.
<h1 class="wp-block-heading">A New Standard For Infection Control</h1>
With the stakes as high as they are, the challenge wasn't just creating a more effective antimicrobial; it was ensuring Silvanex could be safely and efficiently brought to market. Unlike traditional silver-based antimicrobials that require high doses to work, Silvanex achieves superior efficacy at significantly lower concentrations.
That distinction is critical, as excessive silver exposure has been linked to <a href="https://journals.cambridgemedia.com.au/wpr/volume-28-number-4/silver-based-wound-dressings-current-issues-and-future-developments-treating-bacterial-infections">delayed wound healing</a> and <a href="https://www.nature.com/articles/s41598-022-26856-x">cytotoxic effects</a>.
Andira Pharmaceuticals' approach to drug development was both rigorous and deliberate.
"We're not just trying to introduce another antimicrobial," Lambert says. "We're developing something that healthcare providers can trust — something that works better than anything currently available and can be integrated into standard medical practice."
See also: <a href="https://www.benzinga.com/markets/cannabis/25/01/43002904/he-worked-on-producing-oxygen-on-mars-now-he-builds-cannabis-robots-the-fascinating-story-of-sorting-robotics">He Worked On Producing Oxygen On Mars, Now He Builds Cannabis Robots: The Fascinating Story Of Sorting Robotics</a>
Silvanex's formulation is optimized for topical use, making it a strong candidate for wound care, surgical site infection prevention and hospital-acquired infection control. Unlike traditional antibiotics, which must be administered systemically and face significant challenges related to drug resistance, Silvanex is designed to act locally, right at the site of infection.
This topical approach also addresses a major limitation of cannabinoids in antimicrobial research: they lose their antimicrobial properties entirely once they enter the bloodstream.
"Cannabinoids lose their antimicrobial properties entirely once they enter systemic circulation," Lambert explains. "That's why Silvanex will always be used as a topical treatment. The synergy between silver, CBC and CBG remains intact in external applications, where we see the full benefit of its infection-fighting potential."
In the fight against hospital-acquired infections, this represents a major leap forward.
<h1 class="wp-block-heading">Turning Innovation Into Medicine: Silvanex's Road To Market</h1>
Bringing a novel drug to market requires more than just groundbreaking science: it demands years of rigorous testing, regulatory approvals and a strategic path to commercialization.
Andira is now preparing to advance Silvanex through the next critical phases of development, starting with clinical trials. The company's pipeline of Silvanex product candidates includes a topical drug formulated as an anti-infective cream, as well as antimicrobial wound dressings. According to Lambert, the wound dressings are on track for regulatory submission as medical devices, which, if approved, offers a faster pathway to market compared to new drug applications.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51-1024x573.png" alt="" class="wp-image-767659" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51-1536x859.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05122004/Screen-Shot-2025-02-05-at-14.19.51.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The company is currently in preclinical testing, conducting essential toxicology and safety studies to meet the stringent requirements set by regulatory agencies.
"Right now, we're about a year away from entering Phase 1 clinical trials, and our goal is to progress through clinical development as efficiently as possible," Lambert says. "We've conducted extensive preclinical testing and have seen promising results against multiple drug-resistant pathogens, including some on the FDA's QIDP list. While there's no guarantee, we believe Silvanex has strong potential to qualify."
With strategic partnerships in the works, Andira is positioning Silvanex not just as an incremental improvement, but as a potential paradigm shift in antimicrobial treatment.
<h1 class="wp-block-heading">A Critical Moment In Medicine?</h1>
The world is at a crossroads when it comes to fighting superbugs. Without new solutions, drug-resistant infections could turn once-minor ailments into deadly, untreatable threats.
Silvanex represents a potential breakthrough in infection control, offering an alternative where traditional treatments have failed. By leveraging cannabinoids in a way that enhances rather than replaces existing medical solutions, Andira Pharmaceuticals has developed a novel approach to tackling antimicrobial resistance.
With Phase 1 clinical trials on the horizon for the development of Silvanex as a topical drug product and strategic partnerships in motion for the development of Silvanex antimicrobial wound dressings, Andira aims to bring Silvanex to market as efficiently as possible. If successful, this innovation could mark a turning point in infection prevention, helping to curb one of the greatest threats to global health.
Photo: Courtesy of Tinnakorn Jorruang via Shutterstock

Biotech

Cannabis

Health Care

Exclusives

Interview

Cannabis Takes On Superbugs: Could This New Drug 'Change Infection Treatment Forever'?

Whales with a lot of money to spend have taken a noticeably bullish stance on Duolingo.
Looking at options history for Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $121,930 and 7, calls, for a total amount of $713,370.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $540.0 for Duolingo, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Duolingo's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Duolingo's whale trades within a strike price range from $200.0 to $540.0 in the last 30 days. 
<h3>Duolingo Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738781132_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$81.0</td>
<td>$76.5</td>
<td>$81.0</td>
<td>$540.00</td>
<td>$405.0K</td>
<td align="right">65</td>
<td align="right">50</td>
</tr>
<tr>
<td>DUOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$122.5</td>
<td>$119.2</td>
<td>$121.1</td>
<td>$480.00</td>
<td>$96.8K</td>
<td align="right">0</td>
<td align="right">8</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$71.9</td>
<td>$69.1</td>
<td>$71.0</td>
<td>$390.00</td>
<td>$92.3K</td>
<td align="right">24</td>
<td align="right">14</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$42.8</td>
<td>$40.2</td>
<td>$42.0</td>
<td>$420.00</td>
<td>$58.8K</td>
<td align="right">41</td>
<td align="right">14</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$51.8</td>
<td>$49.0</td>
<td>$50.03</td>
<td>$340.00</td>
<td>$50.0K</td>
<td align="right">69</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Duolingo</h3>
Duolingo Inc is a technology company that develops mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include The Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has three predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test.
Following our analysis of the options activities associated with Duolingo, we pivot to a closer look at the company's own performance.
<h3>Duolingo's Current Market Status</h3>
<ul>
<li>Trading volume stands at 463,914, with DUOL's price up by 0.47%, positioned at $387.99.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>What Analysts Are Saying About Duolingo</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $390.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $370. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Duolingo, which currently sits at a price target of $410. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Duolingo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

DUOL

Market Whales and Their Recent Bets on DUOL Options

Financial giants have made a conspicuous bullish move on Capri Holdings. Our analysis of options history for Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) revealed 18 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $694,067, and 6 were calls, valued at $284,260.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $32.5 for Capri Holdings over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Capri Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capri Holdings's whale trades within a strike price range from $15.0 to $32.5 in the last 30 days. 
<h3>Capri Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738781127_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$2.42</td>
<td>$2.41</td>
<td>$2.42</td>
<td>$23.00</td>
<td>$180.7K</td>
<td>2.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$9.6</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$30.00</td>
<td>$114.9K</td>
<td>140</td>
<td>122</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.05</td>
<td>$6.95</td>
<td>$6.95</td>
<td>$27.50</td>
<td>$75.0K</td>
<td>1.1K</td>
<td>109</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$1.21</td>
<td>$1.08</td>
<td>$1.15</td>
<td>$22.50</td>
<td>$57.5K</td>
<td>5.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.92</td>
<td>$1.91</td>
<td>$1.92</td>
<td>$20.00</td>
<td>$57.0K</td>
<td>200</td>
<td>311</td>
</tr>
</tbody>
</table>

<h3>About Capri Holdings</h3>
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Following our analysis of the options activities associated with Capri Holdings, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Capri Holdings</h3>
<ul>
<li>With a trading volume of 7,754,400, the price of CPRI is down by -14.11%, reaching $20.64.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>What The Experts Say On Capri Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $25.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Market Perform rating on Capri Holdings with a target price of $23. 
&#x2A; An analyst from Citigroup upgraded its action to Buy with a price target of $29. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for Capri Holdings, targeting a price of $23. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Capri Holdings with a target price of $23. 
&#x2A; In a positive move, an analyst from Wells Fargo has upgraded their rating to Overweight and adjusted the price target to $28. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capri Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

CPRI

Unpacking the Latest Options Trading Trends in Capri Holdings

Financial giants have made a conspicuous bullish move on Applied Mat. Our analysis of options history for Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) revealed 16 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $311,540, and 10 were calls, valued at $464,157.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $200.0 for Applied Mat, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Applied Mat's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Mat's whale trades within a strike price range from $125.0 to $200.0 in the last 30 days. 
<h3>Applied Mat Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738781122_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$34.35</td>
<td>$34.2</td>
<td>$34.35</td>
<td>$195.00</td>
<td>$130.5K</td>
<td>0</td>
<td align="right">38</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.3</td>
<td>$13.1</td>
<td>$13.24</td>
<td>$175.00</td>
<td>$66.2K</td>
<td>1.1K</td>
<td align="right">52</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$13.35</td>
<td>$13.15</td>
<td>$13.2</td>
<td>$175.00</td>
<td>$66.0K</td>
<td>1.1K</td>
<td align="right">152</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$13.35</td>
<td>$13.1</td>
<td>$13.17</td>
<td>$175.00</td>
<td>$65.8K</td>
<td>1.1K</td>
<td align="right">202</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$19.0</td>
<td>$18.8</td>
<td>$18.9</td>
<td>$180.00</td>
<td>$47.2K</td>
<td>221</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Following our analysis of the options activities associated with Applied Mat, we pivot to a closer look at the company's own performance.
<h3>Current Position of Applied Mat</h3>
<ul>
<li>Currently trading with a volume of 1,896,810, the AMAT's price is up by 0.43%, now at $179.32. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
<h3>What The Experts Say On Applied Mat</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $200.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Applied Mat, targeting a price of $202. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Applied Mat, which currently sits at a price target of $200. 
&#x2A; An analyst from Keybanc has elevated its stance to Overweight, setting a new price target at $225. 
&#x2A; An analyst from Susquehanna has decided to maintain their Neutral rating on Applied Mat, which currently sits at a price target of $165. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on Applied Mat, maintaining a target price of $210. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Applied Mat, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AMAT

This Is What Whales Are Betting On Applied Mat

<a href="https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php" title="https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php">https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php</a>
<a href="https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php" title="https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php">https://www.sfchronicle.com/health/article/seasonal-flu-influenza-california-20145190.php</a>

Comments

Third Bench

Third Bench (THBD) Forecast

Third Bench (OTC:THBD) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga